苦参素联合拉米夫定对慢性乙型肝炎血清HBsAg影响的Meta分析  

Meta analysis of effect of kushenin combined with lamivudine on serum HBsAg in patients with chronic hepatitis B

作　　者：杨诗杰[1] 何强[2] 苏汝好[2] 吴进军[2] 孙丽[2] 王娜[2] 蔡定彬[2] 

机构地区：[1]中国疾病控制中心寄生虫病预防控制所,上海市200025 [2]广东医学院附属医院,广东省湛江市524001

出　　处：《实用医学杂志》2008年第13期2220-2223,共4页The Journal of Practical Medicine

基　　金：广东省科技攻关项目(编号:A98040)

摘　　要：目的:评价苦参素联合拉米夫定对慢性乙型肝炎血清HBsAg的影响。方法:按照系统评价的原则制定检索策略,收集符合纳入标准的研究并采集相关信息进行Meta分析。结果:14篇研究符合纳入标准。疗程为3个月时相对危险度(RR)为2.03,95%可信区间(CI)为(0.85,4.84)。6个月时RR为1.89,95%CI为(1.00,3.56),联合组与对照组差异均无统计学意义。疗程为12个月时RR为2.16,95%CI为(1.30,3.59),两组差异有统计学意义。结论:随着疗程的延长,拉米夫定联合苦参素治疗慢性乙型肝炎血清HBsAg转阴率的疗效有优于单用拉米夫定的趋势。Objective To estimate the effect of kushenin combined with lamivudine for chronic hepatitis B therapy by determing the level of serum HBsAg. Methods Search strategy was formulated according to the Cochrane systematic review, the related data met the inclusion criteria was collected for Meta analysis. Results 14 clinical trials met the inclusion criteria, no statistical significance was found between lamivudine combined with kushenin group and lamivudine group after of 3-month or 6-month treatment with relative risk 2.03,95% confidence interval（0.85,4.84） and relative risk 1.89, 95% confidence interval （1.00,3.56）, respectively. However, after 12-month treatment, the therapeutic effect of lamivudine combined with kushenin was better than that of lamivudine alone, with relative risk 2.16, 95% confidence interval （1.30,3.59）. Conclusion With the prolongation of treating period, there exists a trendency that negative conversion rate of HBsAg in patients treated with kushenin combined with lamivudine becomes higher and higher than that in patients treated with lamivudine alone.

关 键 词：肝炎 乙型 慢性 拉米夫定 META分析 苦参素 乙型肝炎表面抗原 

分 类 号：R512.62[医药卫生—内科学]